CNSDose uses advanced genetic technology to fast-track finding the right antidepressant and dose to improve the prescription of antidepressants. CNSDose brings personalized guidance through precision genetic technology. A simple swab of the cheek quickly guides a clinician’s choice of the antidepressant at the ideal dosage for an individual based on their DNA. It has partnerships with Intermountain Healthcare and the University of Texas Physicians System. It has a product pipeline for genetic guidance of other drug classes in mental health (e.g., ADHD and Alzheimer’s disease). CNSDose has completed accelerators at the Melbourne Accelerator Program (University of Melbourne) and Texas Medical Center.